Oncotype DX Breast Recurrence Score®: A Review of its Use in Early-Stage Breast Cancer

568^ Background: The 21-gene Oncotype DX Recurrence Score (RS) is a validated assay to help inform the appropriate treatment of estrogen receptor-positive (ER+), early stage breast cancer in the adjuvant setting. Treatment traditions regarding choice of adjuvant treatment vary significantly in different countries. This prospective multicenter study is the first to assess the impact of using the Oncotype DX assay in the French clinical setting. Methods: A total of 100 consecutive patients with ER+, HER2-negative, node negative or pN1 (mi) breast cancer were enrolled. Overall treatment recommendation change, change from chemoendocrine to endocrine alone and change from endocrine alone to chemoendocrine treatment were recorded. Medical oncologists completed questionnaires regarding their confidence in their recommendation before and after knowing the patient’s RS. A preliminary analysis was conducted on the first 92 evaluable patients with data available at the time of abstract submission. Final data will be presented at the meeting. Results: Prior to Oncotype DX 49% of patients were recommended chemoendocrine treatment and 51% endocrine treatment alone. After having the RS, 26% were recommended chemoendocrine treatment and 74% endocrine treatment alone. The overall reduction in chemotherapy recommendation from 49% to 26% was significant (p<0.001). Of patients originally recommended chemoendocrine treatment, 58% were changed to endocrine treatment alone after having the RS. Of patients originally recommended endocrine treatment, 11% were changed to chemoendocrine treatment after receiving the RS. There was a significant improvement in physician confidence in treatment recommendations (p=0.002) when using Oncotype DX. Conclusions: These are the first prospective data regarding the impact of using Oncotype DX in France. Using Oncotype DX was associated with a significant change in treatment decisions and an overall reduction in chemotherapy use. The data are consistent with those presented from Germany, Spain, the UK and the US.

Download Full-text

Comparison between Oncotype DX test and standard prognostic criteria in estrogen receptor positive early-stage breast cancer

Einstein (São Paulo) ◽

10.1590/s1679-45082011ao2039 ◽

2011 ◽

Vol 9 (3) ◽

pp. 354-358 ◽

Cited By ~ 3

Author(s):

Marcelo Roberto Pereira Freitas ◽

Sergio Daniel Simon

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Early Stage ◽

Recurrence Score ◽

Oncotype Dx ◽

Early Stage Breast Cancer ◽

Exact Test ◽

Prognostic Criteria ◽

Estrogen Receptor Positive ◽

Kappa Value

ABSTRACT Objective: To compare the prognosis estimated by standard prognostic criteria versus the prognosis estimated by the Oncotype DX. Methods: A retrospective study was performed on 22 patients with positive estrogen receptor, early-stage breast cancer who had an Oncotype DX recurrence score available. Results: Kappa value between Oncotype DX and standard prognostic criteria was: Adjuvant! (K = 0.091), Adjuvant! (Transbig) (K = 0.182) and National Comprehensive Cancer Network (K = 0.091). The Fisher's exact test did not show correlation between Oncotype and standard prognostic criteria. Conclusion: Standard prognostic criteria showed no correlation with Oncotype DX.

Download Full-text

Evaluating Use Characteristics for the Oncotype Dx 21-Gene Recurrence Score and Concordance With Chemotherapy Use in Early-Stage Breast Cancer

Journal of Oncology Practice ◽

10.1200/jop.2012.000638 ◽

2013 ◽

Vol 9 (4) ◽

pp. 182-187 ◽

Cited By ~ 26

Author(s):

Clara Chen ◽

Rahul Dhanda ◽

Wan-Yu Tseng ◽

Michael Forsyth ◽

Debra A. Patt

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Performance Status ◽

Recurrence Score ◽

Oncotype Dx ◽

Early Stage Breast Cancer ◽

Ecog Performance Status

Patients who are younger, have better ECOG performance status, or have higher grade tumors are more likely to undergo recurrence score testing.

Download Full-text

The Effect of Oncotype DX Recurrence Score on Treatment Recommendations for Patients with Estrogen Receptor–Positive Early Stage Breast Cancer and Correlation with Estimation of Recurrence Risk by Breast Cancer Specialists

The Oncologist ◽

10.1634/theoncologist.2011-0045 ◽

2011 ◽

Vol 16 (11) ◽

pp. 1520-1526 ◽

Cited By ~ 65

Author(s):

Jennifer E. Joh ◽

Nicole N. Esposito ◽

John V. Kiluk ◽

Christine Laronga ◽

M. Catherine Lee ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Early Stage ◽

Recurrence Score ◽

Recurrence Risk ◽

Oncotype Dx ◽

Early Stage Breast Cancer ◽

Estrogen Receptor Positive ◽

Cancer Specialists ◽

Oncotype Dx Recurrence Score

Download Full-text

Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-2424 ◽

2019 ◽

Vol 26 (1) ◽

pp. 101-109

Author(s):

Fei Wang ◽

Sonya Reid ◽

Wei Zheng ◽

Tuya Pal ◽

Ingrid Meszoely ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Recurrence Score ◽

Oncotype Dx ◽

Er Positive ◽

Sex Disparity ◽

Breast Recurrence ◽

Positive Breast Cancer

Download Full-text

Can high Ki67 predict distant recurrence in early-stage breast cancer with low Oncotype Dx score?

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e12561 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e12561-e12561

Author(s):

Parvaneh Fallah ◽

Nasser Khleel Mulla ◽

Raquel Aloyz ◽

Olga Aleynikova ◽

Anca Florea ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Risk Group ◽

Early Stage ◽

Recurrence Score ◽

Distant Recurrence ◽

High Risk Group ◽

Low Risk ◽

Oncotype Dx ◽

Early Stage Breast Cancer

e12561 Background: Ki-67 is a marker of proliferating cells. The recurrence score based on the 21-gene breast cancer assay also called Oncotype Dx provides prognostic and predictive information for recurrence in early stage breast cancer patients. We previously showed that there is a moderate correlation between Ki67 and oncotype Dx recurrence score. In this retrospective study, we aimed to examine whether high Ki67 could predict the distant recurrence in early stage breast cancer with low oncotype Dx scores ( < 25). Methods: This retrospective study included 278 consecutive cases of hormone receptor-positive, HER2 negative (T1-2 N0 M0) breast cancer who were diagnosed between 2008 and 2015 with low oncotype Dx ( < 25). Patients’ clinical outcome in terms of distant recurrence after breast surgery was determined up to December 2020 (median follow-up of 7 years). Patients were divided in to low risk (Ki67 < 15%) and high risk (Ki67 > = 15%) groups. Results: Of 278 cases with average and median age of 59 and 60 respectively, 148 (53%) were in Ki67 low risk and 130 (47%) were in Ki67 high risk group. Average and median oncotype Dx were 13.86 and 15 respectively in Ki67 low risk versus 15.23 and 16 respectively in Ki67 high risk group. 13 patients (4%) experienced distant metastasis in lung, liver, bone and skin. Of these 13 cases with average and median oncotype Dx 15.84 and 19 respectively, 12 (92%) were in the Ki67 high risk group and only 1 (8%) belonged to the low risk category. High Ki67 patients were overrepresented in group with recurrent distant metastasis compare to group without recurrent disease (Pearson Chi-Square = 51.18 with 1 degree of freedom and P = < 0.001). Conclusions: Ki67 high patients in the low risk oncotype Dx group are relapsing at a significantly higher rate suggesting that Ki67 combined with low oncotype Dx further refines the risk of distant relapse.

Download Full-text